摘要
吉非替尼是一种口服选择性表皮生长因子受体酪氨酸激酶抑制剂,用于治疗非小细胞肺癌。吉非替尼可引起间质性肺疾病(ILD),引起ILD的平均时间为24～42d,发生率为0.44%～2.0%,病死率为0.12%～0.5%。ILD主要临床表现为呼吸困难、胸闷、干咳和发绀等,胸部影像学检查可见双肺弥漫性浸润性阴影及蜂窝状间质阴影。高龄、男性、吸烟史、ILD史和长时间用药等为吉非替尼致ILD的危险因素。用药期间应进行胸部影像学检查,一旦发现ILD应及时停药,并给予静脉注射大剂量糖皮质激素、吸氧、抗感染等对症支持治疗,一般预后良好。
Gefitinib is a selective inhib tor of the tyrosine kinase activity of the epidermal growth factor receptor, which is used in the treatment of non-small-cell lung cancer. Gefitinib can cause interstitial lung disease （ILD）. The mean time to gefitinib-induced ILD onset is 24-42 days. The incidence of ILD is 0. 44%-2. 0% , and the mortality rate of ILD is 0. 12%-0.5%. The clinical manifestations are dyspnea, respiratory distress, dry cough, and cyanosis. Diffuse infiltration shadow and alveolar interstitial shadow were seen on chest imagine studies. Advanced age, male, smoking history, a previous history of ILD, and the long duration of treatment are th risk factors for gefitinib-induced ILD. During gefitinib therapy, chest imaging should be performed regularly. Once ILD occur, gefitinib should be discontinued, and high-dose 1V glucocorticoid, oxygen inhalation therapy, and anti-infective therapy should be administered. The prognosis is generally good.
出处
《药物不良反应杂志》
2011年第3期165-168,共4页
Adverse Drug Reactions Journal
关键词
间质性肺疾病
吉非替尼
interstitial lung disease
gefitinib
